Brown Advisory Inc. boosted its position in Omeros Corporation (NASDAQ:OMER) by 4.0% during the second quarter, Holdings Channel reports. The institutional investor owned 543,763 shares of the biopharmaceutical company’s stock after buying an additional 21,133 shares during the period. Brown Advisory Inc. owned about 1.39% of Omeros Corporation worth $5,721,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Stifel Financial Corp increased its position in shares of Omeros Corporation by 1.4% in the fourth quarter. Stifel Financial Corp now owns 315,438 shares of the biopharmaceutical company’s stock worth $4,962,000 after buying an additional 4,264 shares in the last quarter. BlackRock Group LTD increased its stake in Omeros Corporation by 64.4% in the first quarter. BlackRock Group LTD now owns 12,080 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 4,734 shares during the period. BlackRock Fund Advisors increased its stake in Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock valued at $22,580,000 after buying an additional 10,605 shares during the period. UBS Group AG increased its stake in Omeros Corporation by 0.8% in the first quarter. UBS Group AG now owns 333,744 shares of the biopharmaceutical company’s stock valued at $5,120,000 after buying an additional 2,631 shares during the period. Finally, Geode Capital Management LLC increased its stake in Omeros Corporation by 7.6% in the first quarter. Geode Capital Management LLC now owns 244,865 shares of the biopharmaceutical company’s stock valued at $3,756,000 after buying an additional 17,276 shares during the period. 47.99% of the stock is owned by institutional investors and hedge funds.

Shares of Omeros Corporation (NASDAQ:OMER) traded up 0.80% on Monday, hitting $11.37. 99,581 shares of the stock were exchanged. Omeros Corporation has a 12 month low of $8.90 and a 12 month high of $16.80. The company has a 50-day moving average price of $11.47 and a 200 day moving average price of $12.29. The company’s market cap is $446.76 million.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.18. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $9.80 million. The company’s quarterly revenue was up 212.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.44) EPS. Equities analysts forecast that Omeros Corporation will post ($1.55) EPS for the current fiscal year.

Several research firms have weighed in on OMER. Maxim Group began coverage on shares of Omeros Corporation in a research note on Saturday, June 4th. They issued a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating and issued a $56.00 price target (down from $62.00) on shares of Omeros Corporation in a research note on Thursday, August 11th. WBB Securities reaffirmed a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a research note on Tuesday, June 14th. Cantor Fitzgerald began coverage on shares of Omeros Corporation in a research note on Thursday, June 2nd. They issued a “buy” rating and a $21.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $35.86.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the sale, the vice president now owns 179,597 shares of the company’s stock, valued at approximately $1,959,403.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $11.56, for a total transaction of $183,804.00. Following the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.